Date: 2013-05-15
Type of information: Capital increase
Company: Genmab (Denmark)
Investors:
Amount: DKK 33.6 million
Funding type:
Planned used:
Others: * On May 15, 2013, Genmab has announced that the company will increase its share capital by 339,926 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of the company or others. The shares are subscribed in cash at the following price per share of nominally DKK 1: 2,625 shares at DKK 31.75, 3,500 shares at DKK 40.41, 5,125 shares at DKK 45.24, 3,375 shares at DKK 46.74, 2,000 shares at DKK 55.85, 1,300 shares at DKK 66.60, 500 shares at DKK 67.50, 3,750 shares at DKK 68.65, 1,500 shares at DKK 77, 127,950 shares at DKK 86, 14,688 shares at DKK 101, 167,363 shares at DKK 114, 2,250 shares at DKK 116 and 4,000 shares at DKK 129.75.
Proceeds to the company are approx. DKK 33.6 million. The increase corresponds to approx. 0.67 % of the company\'s share capital. The increase includes the exercise of 115,000 warrants by President & CEO Jan van de Winkel. This will take Jan van de Winkel\'s personal holding of shares in Genmab A/S from 330,000 to 445,000 shares. The new shares are ordinary shares without any special rights and are freely transferable negotiable instruments. The new shares give rights to dividends and other rights in relation to the company as of subscription, i.e. inter alia full rights to dividends for the financial year 2013. The new shares will be listed on NASDAQ OMX Copenhagen after registration with the Danish Business Authority. Genmab A/S\' current share capital amounts to DKK 50,712,892 and will after the capital increase be DKK 51,052,818. The capital increase is expected to be finalized shortly.
Therapeutic area: Cancer - Oncology
